Abstract: The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.
Type:
Grant
Filed:
October 10, 2018
Date of Patent:
October 18, 2022
Assignee:
Douglas Pharmaceuticals, Ltd.
Inventors:
Paul William Glue, Natalie June Medlicott, Peter William Surman
Abstract: The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.
Type:
Grant
Filed:
June 2, 2020
Date of Patent:
October 18, 2022
Assignee:
Douglas Pharmaceuticals, Ltd.
Inventors:
Paul William Glue, Natalie June Medlicott, Peter William Surman
Abstract: The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
Abstract: The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
Type:
Grant
Filed:
September 10, 2019
Date of Patent:
June 29, 2021
Assignee:
Douglas Pharmaceuticals Ltd.
Inventors:
Paul William Glue, Natalie June Medlicott, Peter William Surman
Abstract: The disclosure provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
December 22, 2020
Assignee:
Douglas Pharmaceuticals, Ltd.
Inventors:
Paul William Glue, Natalie June Medlicott
Abstract: The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
Type:
Grant
Filed:
March 28, 2019
Date of Patent:
August 18, 2020
Assignee:
Douglas Pharmaceuticals, Ltd.
Inventors:
Paul William Glue, Natalie June Medlicott
Abstract: The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
Type:
Grant
Filed:
October 10, 2017
Date of Patent:
October 15, 2019
Assignee:
Douglas Pharmaceuticals, Ltd.
Inventors:
Paul William Glue, Natalie June Medlicott, Peter William Surman
Abstract: The present invention is directed to methods and compositions for topical administration of acitretin. More specifically, the present invention is related to methods and compositions for the treatment or prevention or reduction of symptoms or signs of dermatological conditions using acitretin in a topical administration. More specifically, the present invention is related to methods and compositions containing acitretin which are effective for the treatment or prevention or reduction of symptoms or signs of keratoses, in particular actinic keratosis.
Type:
Application
Filed:
October 1, 2012
Publication date:
April 11, 2013
Applicant:
DOUGLAS PHARMACEUTICALS LTD.
Inventors:
Peter Surman, Fergus Cameron Binnie, Marten Geert Vos